Table 2.
Multivariable outcome analyses of younger patients with de novo acute myeloid leukemia assigned to the genetic-risk groups according to the 2017 ELN genetic risk classification
| Variables in final model | Complete remission | Disease-free survival | Overall survival | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | Pa | HR (95% CI) | Pb | HR (95% CI) | Pb | |
| Favorable-risk groupc | ||||||
| Non-CBF-AML patients | ||||||
| BCOR, mutated vs wild-type | 2.61 (1.14-6.00) | 0.02 | 2.57 (1.12-5.89) | 0.03 | ||
| IDH1, mutated vs wild-type | 1.67 (1.07-2.59) | 0.02 | 1.81 (1.17-2.80) | 0.007 | ||
| PTPN11, mutated vs wild-type | 1.54 (1.02-2.33) | 0.04 | ||||
| SETBP1, mutated vs wild-type | 2.27 (1.10-4.66) | 0.03 | 2.38 (1.20-4.73) | 0.01 | ||
| WT1, mutated vs wild-type | 0.28 (0.10-0.75) | 0.01 | 1.91 (1.14-3.20) | 0.01 | 2.78 (1.72-4.50) | <0.001 |
| ZRSR2, mutated vs wild-type | 0.24 (0.07-0.89) | 0.03 | 2.12 (1.03-4.37) | 0.04 | 2.48 (1.31-4.69) | 0.005 |
| Age, 10-year increase | 1.21 (1.03-1.42) | 0.02 | ||||
| WBC count, 50-unit increase | 1.19 (1.06-1.33) | 0.004 | ||||
| CBF-AML patients | ||||||
| KIT, mutated vs wild-type | 3.31 (1.94-5.63) | <0.001 | 2.12 (1.18-3.81) | 0.01 | ||
| Intermediate-risk groupc | ||||||
| DNMT3A, mutated vs wild-type | 3.02 (1.99-4.59) | <0.001 | 1.85 (1.31-2.62) | <0.001 | ||
| WT1, mutated vs wild-type | 0.31 (0.12-0.81) | 0.02 | 2.15 (1.17-3.94) | 0.01 | 1.98 (1.23-3.16) | 0.005 |
| Age, 10-year increase | 1.31 (1.12-1.52) | <0.001 | ||||
| Hemoglobin level, 1-unit increase | 1.24 (1.02-1.51) | 0.03 | 0.85 (0.77-0.94) | 0.002 | ||
| Platelet count, 50-unit increase | 0.79 (0.68-0.93) | 0.004 | 0.86 (0.75-0.98) | 0.03 | ||
| Sex, male vs female | 0.33 (0.15-0.70) | 0.004 | ||||
| Adverse-risk groupc | ||||||
| IDH2, mutated vs wild-type | 0.57 (0.34-0.95) | 0.03 | ||||
| NRAS, mutated vs wild-type | 3.32 (1.80-6.11) | <0.001 | 1.74 (1.15-2.61) | 0.008 | ||
| TET2, mutated vs wild-type | 1.94 (1.18-3.18) | 0.009 | ||||
| Age, 10-year increase | 1.18 (1.04-1.33) | 0.008 | ||||
| Hemoglobin level | 1.24 (1.05-1.46) | 0.01 | ||||
| Platelet count, 50-unit increase | 0.81 (0.69-0.96) | 0.01 | ||||
| Race, white vs nonwhite | 0.32 (0.15-0.72) | 0.005 | ||||
| WBC count, 50-unit increase | 1.20 (1.06-1.37) | 0.006 | ||||
Variables in the table are in alphabetical order and separated by gene mutations and other clinical characteristics. Multivariable analyses were done separately for CBF- and non-CBF patients within the Favorable-risk group.
Abbreviations: AML, acute myeloid leukemia, CI, confidence interval; CBF, core-binding factor; CR, complete remission; DFS, disease-free survival; ELN, European LeukemiaNet; HR, hazard ratio; OR, odds ratio; OS, overall survival; WBC, white blood cell.
NOTE. An OR <1 (>1) means lower (higher) CR rate for first category listed of a dichotomous variable or higher values of a continuous variable. A HR >1 (<1) corresponds to a higher (lower) risk for first category listed of a dichotomous variable or higher values of a continuous variable. A limited backward selection technique was used to build the final model for achievement of CR, DFS and OS. Variables considered in the model were variables that were significant at the likelihood ratio test P-value <0.20 from the univariable models (detailed in the Supplementary Information).
P-values for CR attainment were determined by logistic regression.
P-values for DFS and OS were determined using Cox proportional hazards regression.
Please see Supplementary Material for variables considered in the multivariable models